GlassScriptPhysician profile
Feroze Momin
NPI 1396728507
$250.41
in general payments reported to CMS, 2019-2025
12 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.35 · 2023: $106 · 2024: $29.17 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.06 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35.20 | 2022 | |
| Celgene Corporation | $28.22 | 2023 | Opdualag |
| Cti Biopharma Corp. | $25.00 | 2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $23.58 | 2022 | |
| Merck Sharp & Dohme LLC | $23.46 | 2023 | Keytruda |
| Morphosys, US INC. | $22.99 | 2022 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Glaxosmithkline, LLC. | $15.16 | 2023 | Shingrix |
| Novartis Pharmaceuticals Corporation | $14.68 | 2024 | |
| Daiichi Sankyo INC. | $14.49 | 2024 | Enhertu |
| Pfizer INC. | $14.05 | 2023 | |
| Seagen INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feroze Momin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.